Skip to main content

Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice

Journal of Zhejiang University SCIENCE B volume 13, pages 894–903 (2012)Cite this article

Abstract

Background and objective

Gonadotropin-releasing hormone (GnRH) plays an important role in the regulation of ovarian function and ovarian cancer cell growth. In this study, we determined whether administration of the GnRH agonist (GnRHa), triporelin, prior to cisplatin treatment affects cisplatin and/or prevents cisplatin-induced ovarian damage.

Methods

nu/nu mice were injected with ovarian cancer OVCAR-3 cells intraperitoneally. After two weeks, the mice were treated with saline (control), cisplatin, GnRHa, or cisplatin plus GnRHa for four weeks. At the end of the experimental protocol, blood, tumor, ovary, and uterine tissues were resected for hematoxylin and eosin (H&E) staining, immunohistochemical analyses of Ki67, nuclear factor-κB (NF-κB), and caspase-3, transmission electron microscopy of apoptosis, or enzyme-linked immunosorbent assay (ELISA) analyses of anti-Mullerian hormone (AMH).

Results

Cisplatin treatment effectively inhibited tumor growth in mice treated with human ovarian cancer cells; however the treatment also induced considerable toxicity. Immunohistochemical analyses showed that Ki67 expression was reduced in cisplatin-treated mice compared to control (P<0.05), but there was no statistically significant differences between cisplatin-treated mice and cisplatin plus GnRHa-treated mice (P>0.05), while expressions of NF-κB and caspase-3 were reduced and induced, respectively, in cisplatin-treated mice and cisplatin plus GnRHa-treated mice. Apoptosis occurred in the GnRHa, cisplatin, and cisplatin plus GnRHa-treated mice, but not in control mice. Ovaries exposed to GnRHa in both GnRHa mice and cisplatin-treated mice (combination group) had significantly more primordial and growth follicles and serum levels of AMH than those in the control mice and cisplatin-treated mice (P<0.05).

Conclusions

Administration of GnRHa to mice significantly decreased the extent of ovarian damage induced by cisplatin, but did not affect the anti-tumor activity of cisplatin.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  • Arencibia, J.M., Schally, A.V., 2000. Luteinizing hormone-releasing hormone as an autocrine growth factor in es-2 ovarian cancer cell line. Int. J. Oncol., 16(5):1009–1013.

    PubMed  CAS  Google Scholar 

  • Asschert, J.G., Vellenga, E., Ruiters, M.H., de Vries, E.G., Asschert, J.G., Vellenga, E., Ruiters, M.H., 1999. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer, 82(2):244–249. [doi:10.1002/(SICI)1097-0215 (19990719)82:2〈244::AID-IJC15〉3.0.CO;2-N]

    PubMed  Article  CAS  Google Scholar 

  • Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M.P., Castronovo, V., 1994. The NF-κB transcription factor and cancer: high expression of NF-κB and IκB related proteins in tumor cell lines. Biochem. Pharmacol., 47(1):145–149. [doi:10.1016/0006-2952(94)90448-0]

    PubMed  Article  CAS  Google Scholar 

  • Carter, B.D., Kaltschmidt, C., Kaltschmidt, B., Offenhäuser, N., Böhm-Matthaei, R., Baeuerle, P.A., Barde, Y.A., 1996. Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science, 272(5261):542–545. [doi:10.1126/science.272.5261.542]

    PubMed  Article  CAS  Google Scholar 

  • Danforth, D.R., Arbogast, L.K., Friedman, C.I., 2005. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil. Steril., 83(5):1333–1338. [doi:10.1016/j.fertnstert.2004.12.030]

    PubMed  Article  CAS  Google Scholar 

  • Emons, G., Schally, A.V., 1994. The use of luteinizing hormone-releasing ormone agonists and antagonists in gynecological cancers. Hum. Reprod., 9(7):1364–1379.

    PubMed  CAS  Google Scholar 

  • Emons, G., Weiss, S., Ortmann, O., Grundker, C., Schulz, K.D., 2000. Luteinizing hormone-releasing hormone (LHRH) might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur. J. Endocrinol., 142(6):665–670. [doi:10.1530/eje.0.1420665]

    PubMed  Article  CAS  Google Scholar 

  • Emons, G., Ortmann, O., Teichert, H.M., Fassl, H., Löhrs, U., Kullander, S., Kauppila, A., Ayalon, D., Schally, A., Oberheuser, F., 1996. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer, 78(7):1452–1460. [doi:10.1002/(SICI)1097-0142(19961 001)78:7〈1452::AID-CNCR12〉3.3.CO;2-5]

    CAS  Google Scholar 

  • Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., Nagata, S., 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391(6662):43–50. [doi:10.1038/34112]

    PubMed  Article  CAS  Google Scholar 

  • Grilli, M., Pizzi, M., Memo, M., Spano, P., 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science, 274(5291):1383–1385. [doi:10.1126/science.274.5291.1383]

    PubMed  Article  CAS  Google Scholar 

  • Grimm, S., Bauer, M.K., Baeuerle, P.A., Schulze-Osthoff, K., 1996. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J. Cell Biol., 134(1):13–23. [doi:10.1083/jcb.134.1.13]

    PubMed  Article  CAS  Google Scholar 

  • Gründker, C., Schulz, K., Günthert, A.R., Emons, G., 2000. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J. Clin. Endocrinol. Metab., 85(10):3815–3820. [doi:10.1210/jc.85.10.3815]

    PubMed  Article  Google Scholar 

  • Gründker, C., Günthert, A.R., Westphalen, S., Emons, G., 2002a. Biology of the GnRH system in human gynecological cancers. Eur. J. Endocrinol., 146(1):1–14. [doi:10.1530/eje.0.1460001]

    PubMed  Article  Google Scholar 

  • Gründker, C., Günthert, A.R., Millar, R.P., Emons, G., 2002b. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab., 87(3):1427–1430. [doi:10.1210/jc.87.3.1427]

    PubMed  Article  Google Scholar 

  • Kang, S.K., Cheng, K.W., Nathwani, P.S., Choi, K.C., Leung, P.C., 2000. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine, 13(3):297–304. [doi:10.1385/ENDO:13:3:297]

    PubMed  Article  CAS  Google Scholar 

  • Kim, K.Y., Choi, K.C., Auersperg, N.K., Leung, P.C., 2006. Mechanism of gonadotropin releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr. Relat. Cancer, 13(1):211–220. [doi:10. 1677/erc.1.01033]

    PubMed  Article  CAS  Google Scholar 

  • Imai, A., Takagi, A., Horibe, S., Takagi, H., Tamaya, T., 1998. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J. Clin. Endocrinol. Metab., 83(2):427–431. [doi:10.1210/jc.83.2.427]

    PubMed  Article  CAS  Google Scholar 

  • Imai, A., Ohno, T., Iida, K., Fuseya, T., Furui, T., Tamaya, T., 1994. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer, 74(9):2555–2561. [doi:10.1002/1097-0142(19941101)74:9〈2555::AID-CNCR 2820740925〉3.0.CO;2-X]

    CAS  Google Scholar 

  • Janssens, R.M., Brus, L., Cahill, D.J., Huirne, J.A., Schoemaker, J., Lambalk, C.B., 2000. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum. Reprod. Update, 6(5):505–518. [doi:10.1093/humupd/6.5.505]

    PubMed  Article  CAS  Google Scholar 

  • Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J., 2008. Cancer statistics, 2008. CA: Cancer J. Clin., 58(2):71–96. [doi:10.3322/CA.2007.0010]

    Article  Google Scholar 

  • Meirow, D., Lewis, H., Nugent, D., Epstein, M., 1999. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum. Reprod., 14(7):1903–1907. [doi:10.1093/humrep/14.7.1903]

    PubMed  Article  CAS  Google Scholar 

  • Meirow, D., Assad, G., Dor, J., Rabinovici, J., 2004. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum. Reprod., 19(6):1294–1299. [doi:10.1093/humrep/deh257]

    PubMed  Article  CAS  Google Scholar 

  • Myers, M., Britt, K.L., Wreford, N.G., Ebling, F.J., Kerr, J.B., 2004. Methods for quantifying follicular numbers within the mouse ovary. Reproduction, 127(5):569–580. [doi:10.1530/rep.1.00095]

    PubMed  Article  CAS  Google Scholar 

  • Pereira, S.G., Oakley, F., 2008. Nuclear factor-kappaB1: regulation and function. Int. J. Biochem. Cell Biol., 40(8):1425–1430. [doi:10.1016/j.biocel.2007.05.004]

    PubMed  Article  CAS  Google Scholar 

  • Seppänen, M., Henttinen, T., Lin, L., Punnonen, J., Grénman, S., Punnonen, R., Vihko, K.K., 1998. Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncol. Res., 10(11–12):575–589.

    PubMed  Google Scholar 

  • Shibata, S., Sato, H., Ota, H., Karube, A., Takahashi, O., Tanaka, T., 1997. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol. Oncol., 66(2):217–221. [doi:10.1006/gyno.1997.4746]

    PubMed  Article  CAS  Google Scholar 

  • Stoffel, A., Chaurushiya, M., Singh, B., Levine, A.J., 2004. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. PNAS, 101(24):9079–9084. [doi:10.1073/pnas.0402415101]

    PubMed  Article  CAS  Google Scholar 

  • Sun, X.F., Zhang, H., 2007. NF-κB and NF-κBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol., 22(12):1387–1398.

    PubMed  CAS  Google Scholar 

  • Tang, X., Yano, T., Osuga, Y., Matsumi, H., Yano, N., Xu, J., Wada, O., Koga, K., Kugu, K., Tsutsumi, O., et al., 2002. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH releasing hormone antagonist Cetrorelix. J. Clin. Endocrinol. Metab., 87(8):3721–3727. [doi:10.1210/jc.87.8.3721]

    PubMed  Article  CAS  Google Scholar 

  • Völker, P., Gründker, C., Schmidt, O., Schulz, K.D., Emons, G., 2002. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian andendometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol., 186(2):171–179. [doi:10.1067/mob.2002.119633]

    PubMed  Article  Google Scholar 

  • Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V., Baldwin, A.S.Jr., 1998. NF-kappaB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281(5383): 1680–1683. [doi:10.1126/science.281.5383.1680]

    PubMed  Article  CAS  Google Scholar 

  • Wu, M., Lee, H., Ballas, R., 1996. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15(17): 4682–4690.

    PubMed  CAS  Google Scholar 

  • Zou, H., Henzel, W.J., Liu, X., Lutschg, A., Wang, X., 1997. A human protein homologues to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90(3):405–413. [doi:10.1016/S0092-8674(00)80501-2]

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China

    Qiong-yan Lin, Hui-nan Weng, Xiu-jie Sheng, Qing-ping Jiang & Zhi-ying Yang

  2. Department of Obstetrics and Gynecology, Zhujiang Hospital, Nanfang Medical University, Guangzhou, 510282, China

    Yi-feng Wang

Authors
  1. Qiong-yan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi-feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui-nan Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiu-jie Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qing-ping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhi-ying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-feng Wang.

Additional information

Project (No. 7002691) supported by the Guangdong Provincial Natural Science Foundation of China

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lin, Qy., Wang, Yf., Weng, Hn. et al. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice. J. Zhejiang Univ. Sci. B 13, 894–903 (2012). https://doi.org/10.1631/jzus.B1100369

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1100369

Key words

  • Gonadotrophin-releasing hormone
  • Cisplatin
  • Ovarian cancer
  • Animal experiment

CLC number

  • R711.75